Is Vor Biopharma Inc. (VOR) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 5.1% / 30% | 14.6% / 30% | 0.0% / 30% | N/A | ✓ HALAL |
| DJIM | 5.1% / 33% | 14.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| MSCI | 22.3% / 33% | 64.3% / 33% | 0.0% / 33% | N/A | ✗ NOT HALAL |
| S&P | 5.1% / 33% | 14.6% / 33% | 0.0% / 33% | N/A | ✓ HALAL |
| FTSE | 22.3% / 33% | 64.3% / 33% | 0.0% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Assets (ROA) | -144.3% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$100M |
| Free Cash Flow | -$100M |
| Total Debt | $32M |
| Current Ratio | 9.2 |
| Total Assets | $143M |
Price & Trading
| Last Close | $13.57 |
| 50-Day MA | $14.23 |
| 200-Day MA | $23.59 |
| Avg Volume | 906K |
| Beta | 2.0 |
|
52-Week Range
$2.62
| |
About Vor Biopharma Inc. (VOR)
Vor Biopharma Inc. operates as a clinical-stage cell and genome engineering company. The company offers the Vor Bio platform, a technology platform for the treatment of acute myeloid leukemia (AML) and other blood cancers. It develops tremtelectogene empogeditemcel (trem-cel), a genome-edited hematopoietic stem and progenitor allogeneic donor product candidate to treat acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and other blood cancers; trem-cel in combination with Mylotarg to treat patients in VBP101, which is in phase 1 / 2; and VCAR33, a CAR-T therapy designed to target CD33, which is under preclinical studies to treat AML post-transplant. The company also develops trem-cel + VCAR33 treatment system, CD33-directed CAR-T program, which is under pre-clinical studies for the treatment of AML; VADC45 for the treatment of hematologic malignancies, conditioning, and immune reset, which is under preclinical studies; and CD33-CLL1 treatment system made with CD33-CLL1 multiplex-edited HSC therapy and a CD33-CLL1 multi-specific CAR-T therapy, which is under preclinical studies for the treatment of AML. It has a license agreement with Columbia University and the National Institutes of Health for patents; and with Editas Medicine, Inc. for ex-vivo Cas9 gene-edited HSC therapies for the treatment and/or prevention of hematological malignancies. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is Vor Biopharma Inc. (VOR) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), Vor Biopharma Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is Vor Biopharma Inc.'s debt ratio?
Vor Biopharma Inc.'s debt ratio is 5.1% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 22.3%.
What are Vor Biopharma Inc.'s key financial metrics?
Vor Biopharma Inc. has a market capitalization of $601M.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.